Life Biosciences has dosed the first participant in its ER-100 Phase 1 trial, moving partial epigenetic reprogramming from FDA clearance to active human testing.
A March 2026 Nature Aging review by 25+ scientists from the University of Oslo and international collaborators consolidates the evidence for NAD+ in neurodegenerative disease. Here's what the science says — and what it doesn't.
Senolytics promised to extend healthspan by clearing senescent cells. But recent clinical trial setbacks have cooled the hype. Here's the real state of the field in 2026: which companies are advancing, what failed, what clinics offer, and what the science actually supports.
UT Health San Antonio launches a National Institute on Aging-funded rapamycin trial with 84 older adults—one of the largest longevity-focused clinical studies to date. The shift: from off-label speculation to evidence-based dosing.
The U.S. government's ARPA-H launches the PROSPR program: $144M over five years to identify early aging biomarkers and run the first clinical trials explicitly aimed at extending healthy lifespan.
A systematic review in Nature Metabolism concludes that clinical evidence for NAD+ supplementation in humans remains scarce and results are heterogeneous. More research needed.